AUNA Quote, Financials, Valuation and Earnings

Alvotech has a net margin of 4.74% compared to Auna SA's net margin of -4.62%. Auna SA's return on equity of 11.53% beat Alvotech's return on equity of --.

Auna SA has a consensus price target of $7.20, signalling upside risk potential of 43.43%. On the other hand Alvotech has an analysts' consensus of $18.83 which suggests that it could grow by 395.61%. Given that Alvotech has higher upside potential than Auna SA, analysts believe Alvotech is more attractive than Auna SA.

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alvotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alvotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auna SA pays -- of its earnings as a dividend. Alvotech pays out -- of its earnings as a dividend.

Auna SA quarterly revenues are $316.1M, which are larger than Alvotech quarterly revenues of $113.7M. Auna SA's net income of $15M is higher than Alvotech's net income of -$5.3M. Notably, Auna SA's price-to-earnings ratio is 7.27x while Alvotech's PE ratio is 16.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.32x versus 2.09x for Alvotech. Usually stocks with elevated PS ratios are considered overvalued.

Eurofins Scientific SE has a net margin of 4.74% compared to Auna SA's net margin of --. Auna SA's return on equity of 11.53% beat Eurofins Scientific SE's return on equity of 8.55%.

Auna SA has a consensus price target of $7.20, signalling upside risk potential of 43.43%. On the other hand Eurofins Scientific SE has an analysts' consensus of -- which suggests that it could fall by --. Given that Auna SA has higher upside potential than Eurofins Scientific SE, analysts believe Auna SA is more attractive than Eurofins Scientific SE.

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eurofins Scientific SE has a beta of 0.682, suggesting its less volatile than the S&P 500 by 31.796%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eurofins Scientific SE offers a yield of 1.59% to investors and pays a quarterly dividend of $0.68 per share. Auna SA pays -- of its earnings as a dividend. Eurofins Scientific SE pays out 28.14% of its earnings as a dividend. Eurofins Scientific SE's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Auna SA quarterly revenues are $316.1M, which are larger than Eurofins Scientific SE quarterly revenues of --. Auna SA's net income of $15M is higher than Eurofins Scientific SE's net income of --. Notably, Auna SA's price-to-earnings ratio is 7.27x while Eurofins Scientific SE's PE ratio is 26.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.32x versus 1.74x for Eurofins Scientific SE. Usually stocks with elevated PS ratios are considered overvalued.

PACS Group, Inc. has a net margin of 4.74% compared to Auna SA's net margin of 4.4%. Auna SA's return on equity of 11.53% beat PACS Group, Inc.'s return on equity of 23.27%.

Auna SA has a consensus price target of $7.20, signalling upside risk potential of 43.43%. On the other hand PACS Group, Inc. has an analysts' consensus of $46.00 which suggests that it could grow by 23.68%. Given that Auna SA has higher upside potential than PACS Group, Inc., analysts believe Auna SA is more attractive than PACS Group, Inc..

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PACS Group, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PACS Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auna SA pays -- of its earnings as a dividend. PACS Group, Inc. pays out -- of its earnings as a dividend.

Auna SA quarterly revenues are $316.1M, which are smaller than PACS Group, Inc. quarterly revenues of $1.4B. Auna SA's net income of $15M is lower than PACS Group, Inc.'s net income of $59.8M. Notably, Auna SA's price-to-earnings ratio is 7.27x while PACS Group, Inc.'s PE ratio is 31.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.32x versus 1.14x for PACS Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sofgen Pharma SA has a net margin of 4.74% compared to Auna SA's net margin of --. Auna SA's return on equity of 11.53% beat Sofgen Pharma SA's return on equity of --.

Auna SA has a consensus price target of $7.20, signalling upside risk potential of 43.43%. On the other hand Sofgen Pharma SA has an analysts' consensus of -- which suggests that it could grow by 20561.16%. Given that Sofgen Pharma SA has higher upside potential than Auna SA, analysts believe Sofgen Pharma SA is more attractive than Auna SA.

Auna SA has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sofgen Pharma SA has a beta of 63.524, suggesting its more volatile than the S&P 500 by 6252.39%.

Auna SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sofgen Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Auna SA pays -- of its earnings as a dividend. Sofgen Pharma SA pays out -- of its earnings as a dividend.

Auna SA quarterly revenues are $316.1M, which are larger than Sofgen Pharma SA quarterly revenues of --. Auna SA's net income of $15M is higher than Sofgen Pharma SA's net income of --. Notably, Auna SA's price-to-earnings ratio is 7.27x while Sofgen Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Auna SA is 0.32x versus 0.01x for Sofgen Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.